News Releases

submenu

MINNEAPOLIS/ST. PAUL (February 28, 2017) – Survivors of childhood cancers have fewer secondary cancers, according to new research from the Masonic Cancer Center, University of Minnesota and St. Jude Children’s Research Hospital. Compared with those diagnosed in the 1970s, patients diagnosed after 1990 are experiencing better outcomes. Researchers believe the difference comes from a reduction in exposure to therapeutic radiation.
 

Drs. Modiano and Borgatti with dog Valky

MINNEAPOLIS/ST.PAUL (February 13, 2017) – A breakthrough trial at the University of Minnesota testing a new UMN-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA). The results were published today in the journal Molecular Cancer Therapeutics.

Dr. Robert Kratzke

MINNEAPOLIS/ST. PAUL (December 23, 2016) – The Big Ten Cancer Research Consortium (Big Ten CRC) elected Robert Kratzke, M.D., lung cancer researcher, Masonic Cancer Center, University of Minnesota and associate professor in the University of Minnesota Medical School's Department of Medicine, as its inaugural Steering Committee Chair. Kratzke will lead the initiative to transform cancer research through collaboration across Big Ten universities.

Reuben Harris, PhD

MINNEAPOLIS/ST. PAUL (December 19, 2016) – Unprecedented images of cancer genome-mutating enzymes acting on DNA provide vital clues into how the enzymes work to promote tumor evolution and drive poor disease outcomes. These images, revealed by University of Minnesota researchers, provide the first ever high-resolution pictures of molecular complexes formed between DNA and the human APOBEC3A and APOBEC3B enzymes.
 

Heather Nelson

A new study in JAMA Oncology finds that antibodies to human papillomavirus detectable in blood serum are reliable indicators of five-year head and neck cancer survival

Scott Dehm PhD

MINNEAPOLIS/ST. PAUL (November 30, 2016) – Frequent genetic rearrangements in the androgen receptor could be limiting treatment options for prostate cancer patients, according to new research out of the University of Minnesota. Currently, the main treatment for prostate cancer inhibits androgen receptor activity. However, the new paper identified frequent rearrangements in the metastases of prostate cancer, allowing cancer cells to accumulate a variety of receptor forms and increasing resistance to treatments.

research symposium graphic

The annual event aims to spur new ideas and collaborations toward developing new cancer research

Gene map slicer

Recognition will help further research on exploring genetic connections to breast cancer

Pages

Giving to cancer

Predicting cancer's next move

With a physics-based research approach, Masonic Cancer Center scientists are looking for clues to stop the most unstoppable cancers
...

Treatment, precisely

A national, multipronged clinical study matches cancer patients with investigational treatments designed to attack their specific tumors
...

Silver lining

A woman faced with colon cancer inspired thousands to give and get screened

Even during treatment for Stage IV colon cancer, Danna Mezin was surprisingly energetic. The former UnitedHealthcare executive and her husband, Dick Koats, created the MezinKoats Colon Cancer Research Fund at the...

'How lucky'

A little girl with a rare blood cancer receives a lifesaving bone marrow transplant—and a second chance at a full life—from her big brother
...